AMENDMENTS TO THE SPECIFICATION:

Replace the paragraph bridging pages 9-10, beginning at page 9, line 30 as follows:

As regards an immunogenic polypeptide of the early type, the choice is advantageously made to use a polypeptide derived from E6 or E7, modified in particular so as to have a membrane location. Given the observations recalled above on the transforming power, there is preferably used a nononcogenic variant mutated in the region involved in the process of cell transformation. Such variants are described in the literature (Munger et al., 1989, EMBO J., *8*, 4099-4105; Crook et al., 1991, Cell 67, 547-556; Heck et al., 1992, Proc. Natl. Acad. Sci. USA *89*, 4442-4446; Phelps et al., 1992, J. Virol. *66*, 2148-2427). An immunogenic polypeptide which is particularly suitable for the purpose of the present invention is the HPV-16 E6 antigen deleted for residues 111-115 (+1, representing the first amino acid of the native viral antigen) and fused with the secretory and anchoring signals of the measles F protein (SEQ ID NO:1). It is also possible to use the HPV-16 ~~E6~~ E7 antigen deleted for residues 22 to 25 and fused with the anchoring and secretory sequences of the rabies glycoprotein (SEQ ID NO:2).

Please insert the following section heading before the paragraph beginning at line 27 of page 27:

Brief Description of the Drawings

Please replace the current Abstract, appearing on a separate sheet appended to the application after the claims, with an amended Abstract as follows:

~~The invention concerns an antitumoral composition comprising~~ Antitumoral compositions can comprise as therapeutic agent one or several immunogenic polypeptides, of which at least one is modified so as to have a cell location different from its native location. ~~The invention also concerns a composition~~ Compositions can be based on a recombinant vector expressing ~~said~~ such an immunogenic polypeptide. ~~It further concerns a~~ A recombinant vector comprising at least the sequences coding for an immunogenic polypeptide originating from a precocious and/or tardive region of a papillomavirus having a modified location and a viral particle comprising said vector is also described. Finally, ~~it concerns the~~ therapeutic ~~use~~ uses of ~~said~~ such a composition, ~~said~~ such a recombinant vector and ~~said~~ such a viral particle are described.